Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Inclusion Criteria

• •Histological confirmation of adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable
• •Progression, intolerance, or contraindication to a fluoropyrimidine (e.g., 5- fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ziv-aflibercept, or ramucirumab), and an anti-PD-1 monoclonal antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins (dMMR) or is microsatellite instability-high (MSI-H)
• •For patients with KRAS and NRAS wild-type tumors, progression, intolerance, or contraindication to an anti-EGFR monoclonal antibody (cetuximab or panitumumab)
• •* Note: If tissue is known to be positive for HER2 expression (IHC 3+) or the tumor has ERBB2 (HER2) amplification detected by a Clinical Laboratory Improvement Act (CLIA)-certified assay, prior treatment with anti-EGFR therapy is not required
• •At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1) that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
• •Life expectancy \>= 3 months per estimation of investigator
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
• •Capable of understanding and complying with the protocol requirements and has signed the informed consent document
• •Satisfy at least one of the following two conditions:
• •* Willing and able to provide blood sample for screening purposes
• •* Guardant 360 testing completed =\< 60 days prior to registration